Showing results (121-130 of 214) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancyG T Budd, S Murthy, J Finke, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
FEMS Immunology and Medical Microbiology|February 15, 2001
Study on the pathophysiology of experimental Burkholderia pseudomallei infection in miceY P Gauthier, R M Hagen, G S Brochier, et al.
Zeitschrift Fur Erkrankungen Der Atmungsorgane|January 1, 1990
[Comparative study of parenteral and oral immunization against influenza in a large clinical trial. 2. Results of immunologic studies]H Tischner, M Popp, N T Hien, et al.
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.
Clinical and Diagnostic Laboratory Immunology|January 5, 2000
Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCRR Grunow, W Splettstoesser, S McDonald, et al.
Oncogene|May 1, 2012
Tumor-derived macrophage migration inhibitory factor promotes an autocrine loop that enhances renal cell carcinomaW Du, B M Wright, X Li, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2012
Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantationP Hasselblatt, K Drognitz, K Potthoff, et al.
Journal of Biological Response Modifiers|December 1, 1990
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effectsR M Bukowski, S Murthy, J Sergi, et al.
Investigational New Drugs|May 1, 1993
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.
Pageof 22